The Global Drugs for Vulvovaginal Candidiasis Market Size was estimated at USD 831.60 million in 2023 and is projected to reach USD 909.31 million by 2029, exhibiting a CAGR of 1.50% during the forecast period.
The USA market for Global Drugs for Vulvovaginal Candidiasis market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Drugs for Vulvovaginal Candidiasis market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Drugs for Vulvovaginal Candidiasis market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Report Overview:
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
This report provides a deep insight into the global Drugs for Vulvovaginal Candidiasis market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porters five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Vulvovaginal Candidiasis Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Vulvovaginal Candidiasis market in any manner.
Global Drugs for Vulvovaginal Candidiasis Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Bayer
- Perrigo
- J & J
- Pfizer
- Bristol-Myers Squibb
- Effik
- Teva
- Sanofi
- Cisen Pharmaceutical
- Kingyork Group
Market Segmentation (by Type)
Market Segmentation (by Application)
- Hospital & Clinic
- Pharmacy
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Drugs for Vulvovaginal Candidiasis Market
- Overview of the regional outlook of the Drugs for Vulvovaginal Candidiasis Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
- Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Vulvovaginal Candidiasis Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Vulvovaginal Candidiasis
1.2 Key Market Segments
1.2.1 Drugs for Vulvovaginal Candidiasis Segment by Type
1.2.2 Drugs for Vulvovaginal Candidiasis Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Drugs for Vulvovaginal Candidiasis Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Drugs for Vulvovaginal Candidiasis Market Competitive Landscape
3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2019-2024)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2019-2024)
3.3 Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Drugs for Vulvovaginal Candidiasis Sales Sites, Area Served, Product Type
3.6 Drugs for Vulvovaginal Candidiasis Market Competitive Situation and Trends
3.6.1 Drugs for Vulvovaginal Candidiasis Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
4.1 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Drugs for Vulvovaginal Candidiasis Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Drugs for Vulvovaginal Candidiasis Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2019-2024)
6.3 Global Drugs for Vulvovaginal Candidiasis Market Size Market Share by Type (2019-2024)
6.4 Global Drugs for Vulvovaginal Candidiasis Price by Type (2019-2024)
7 Drugs for Vulvovaginal Candidiasis Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Vulvovaginal Candidiasis Market Sales by Application (2019-2024)
7.3 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) by Application (2019-2024)
7.4 Global Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Application (2019-2024)
8 Drugs for Vulvovaginal Candidiasis Market Segmentation by Region
8.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region
8.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region
8.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Vulvovaginal Candidiasis Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Bayer
9.1.1 Bayer Drugs for Vulvovaginal Candidiasis Basic Information
9.1.2 Bayer Drugs for Vulvovaginal Candidiasis Product Overview
9.1.3 Bayer Drugs for Vulvovaginal Candidiasis Product Market Performance
9.1.4 Bayer Business Overview
9.1.5 Bayer Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.1.6 Bayer Recent Developments
9.2 Perrigo
9.2.1 Perrigo Drugs for Vulvovaginal Candidiasis Basic Information
9.2.2 Perrigo Drugs for Vulvovaginal Candidiasis Product Overview
9.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Product Market Performance
9.2.4 Perrigo Business Overview
9.2.5 Perrigo Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.2.6 Perrigo Recent Developments
9.3 J and J
9.3.1 J and J Drugs for Vulvovaginal Candidiasis Basic Information
9.3.2 J and J Drugs for Vulvovaginal Candidiasis Product Overview
9.3.3 J and J Drugs for Vulvovaginal Candidiasis Product Market Performance
9.3.4 J and J Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.3.5 J and J Business Overview
9.3.6 J and J Recent Developments
9.4 Pfizer
9.4.1 Pfizer Drugs for Vulvovaginal Candidiasis Basic Information
9.4.2 Pfizer Drugs for Vulvovaginal Candidiasis Product Overview
9.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Product Market Performance
9.4.4 Pfizer Business Overview
9.4.5 Pfizer Recent Developments
9.5 Bristol-Myers Squibb
9.5.1 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Basic Information
9.5.2 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Overview
9.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Market Performance
9.5.4 Bristol-Myers Squibb Business Overview
9.5.5 Bristol-Myers Squibb Recent Developments
9.6 Effik
9.6.1 Effik Drugs for Vulvovaginal Candidiasis Basic Information
9.6.2 Effik Drugs for Vulvovaginal Candidiasis Product Overview
9.6.3 Effik Drugs for Vulvovaginal Candidiasis Product Market Performance
9.6.4 Effik Business Overview
9.6.5 Effik Recent Developments
9.7 Teva
9.7.1 Teva Drugs for Vulvovaginal Candidiasis Basic Information
9.7.2 Teva Drugs for Vulvovaginal Candidiasis Product Overview
9.7.3 Teva Drugs for Vulvovaginal Candidiasis Product Market Performance
9.7.4 Teva Business Overview
9.7.5 Teva Recent Developments
9.8 Sanofi
9.8.1 Sanofi Drugs for Vulvovaginal Candidiasis Basic Information
9.8.2 Sanofi Drugs for Vulvovaginal Candidiasis Product Overview
9.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Product Market Performance
9.8.4 Sanofi Business Overview
9.8.5 Sanofi Recent Developments
9.9 Cisen Pharmaceutical
9.9.1 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Basic Information
9.9.2 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Overview
9.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Market Performance
9.9.4 Cisen Pharmaceutical Business Overview
9.9.5 Cisen Pharmaceutical Recent Developments
9.10 Kingyork Group
9.10.1 Kingyork Group Drugs for Vulvovaginal Candidiasis Basic Information
9.10.2 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Overview
9.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Market Performance
9.10.4 Kingyork Group Business Overview
9.10.5 Kingyork Group Recent Developments
10 Drugs for Vulvovaginal Candidiasis Market Forecast by Region
10.1 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast
10.2 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country
10.2.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size Forecast by Region
10.2.4 South America Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Vulvovaginal Candidiasis by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Drugs for Vulvovaginal Candidiasis by Type (2025-2030)
11.1.2 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Drugs for Vulvovaginal Candidiasis by Type (2025-2030)
11.2 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2025-2030)
11.2.1 Global Drugs for Vulvovaginal Candidiasis Sales (Kilotons) Forecast by Application
11.2.2 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Drugs for Vulvovaginal Candidiasis Market Size Comparison by Region (M USD)
Table 5. Global Drugs for Vulvovaginal Candidiasis Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Drugs for Vulvovaginal Candidiasis Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2022)
Table 10. Global Market Drugs for Vulvovaginal Candidiasis Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Drugs for Vulvovaginal Candidiasis Sales Sites and Area Served
Table 12. Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 13. Global Drugs for Vulvovaginal Candidiasis Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Drugs for Vulvovaginal Candidiasis
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 22. Global Drugs for Vulvovaginal Candidiasis Sales by Type (Kilotons)
Table 23. Global Drugs for Vulvovaginal Candidiasis Market Size by Type (M USD)
Table 24. Global Drugs for Vulvovaginal Candidiasis Sales (Kilotons) by Type (2019-2024)
Table 25. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2019-2024)
Table 26. Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) by Type (2019-2024)
Table 27. Global Drugs for Vulvovaginal Candidiasis Market Size Share by Type (2019-2024)
Table 28. Global Drugs for Vulvovaginal Candidiasis Price (USD/Ton) by Type (2019-2024)
Table 29. Global Drugs for Vulvovaginal Candidiasis Sales (Kilotons) by Application
Table 30. Global Drugs for Vulvovaginal Candidiasis Market Size by Application
Table 31. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2019-2024)
Table 33. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2019-2024) & (M USD)
Table 34. Global Drugs for Vulvovaginal Candidiasis Market Share by Application (2019-2024)
Table 35. Global Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Application (2019-2024)
Table 36. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2019-2024)
Table 38. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Drugs for Vulvovaginal Candidiasis Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Region (2019-2024) & (Kilotons)
Table 43. Bayer Drugs for Vulvovaginal Candidiasis Basic Information
Table 44. Bayer Drugs for Vulvovaginal Candidiasis Product Overview
Table 45. Bayer Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Bayer Business Overview
Table 47. Bayer Drugs for Vulvovaginal Candidiasis SWOT Analysis
Table 48. Bayer Recent Developments
Table 49. Perrigo Drugs for Vulvovaginal Candidiasis Basic Information
Table 50. Perrigo Drugs for Vulvovaginal Candidiasis Product Overview
Table 51. Perrigo Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Perrigo Business Overview
Table 53. Perrigo Drugs for Vulvovaginal Candidiasis SWOT Analysis
Table 54. Perrigo Recent Developments
Table 55. J and J Drugs for Vulvovaginal Candidiasis Basic Information
Table 56. J and J Drugs for Vulvovaginal Candidiasis Product Overview
Table 57. J and J Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. J and J Drugs for Vulvovaginal Candidiasis SWOT Analysis
Table 59. J and J Business Overview
Table 60. J and J Recent Developments
Table 61. Pfizer Drugs for Vulvovaginal Candidiasis Basic Information
Table 62. Pfizer Drugs for Vulvovaginal Candidiasis Product Overview
Table 63. Pfizer Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Pfizer Business Overview
Table 65. Pfizer Recent Developments
Table 66. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Basic Information
Table 67. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Overview
Table 68. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Bristol-Myers Squibb Business Overview
Table 70. Bristol-Myers Squibb Recent Developments
Table 71. Effik Drugs for Vulvovaginal Candidiasis Basic Information
Table 72. Effik Drugs for Vulvovaginal Candidiasis Product Overview
Table 73. Effik Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Effik Business Overview
Table 75. Effik Recent Developments
Table 76. Teva Drugs for Vulvovaginal Candidiasis Basic Information
Table 77. Teva Drugs for Vulvovaginal Candidiasis Product Overview
Table 78. Teva Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Teva Business Overview
Table 80. Teva Recent Developments
Table 81. Sanofi Drugs for Vulvovaginal Candidiasis Basic Information
Table 82. Sanofi Drugs for Vulvovaginal Candidiasis Product Overview
Table 83. Sanofi Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Sanofi Business Overview
Table 85. Sanofi Recent Developments
Table 86. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Basic Information
Table 87. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Overview
Table 88. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Cisen Pharmaceutical Business Overview
Table 90. Cisen Pharmaceutical Recent Developments
Table 91. Kingyork Group Drugs for Vulvovaginal Candidiasis Basic Information
Table 92. Kingyork Group Drugs for Vulvovaginal Candidiasis Product Overview
Table 93. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Kingyork Group Business Overview
Table 95. Kingyork Group Recent Developments
Table 96. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Drugs for Vulvovaginal Candidiasis Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Drugs for Vulvovaginal Candidiasis Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Drugs for Vulvovaginal Candidiasis Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Drugs for Vulvovaginal Candidiasis Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Drugs for Vulvovaginal Candidiasis Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global Drugs for Vulvovaginal Candidiasis Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Drugs for Vulvovaginal Candidiasis
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Drugs for Vulvovaginal Candidiasis Market Size (M USD), 2019-2030
Figure 5. Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) (2019-2030)
Figure 6. Global Drugs for Vulvovaginal Candidiasis Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Drugs for Vulvovaginal Candidiasis Market Size by Country (M USD)
Figure 11. Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturers in 2023
Figure 12. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers in 2023
Figure 13. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Drugs for Vulvovaginal Candidiasis Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Drugs for Vulvovaginal Candidiasis Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Drugs for Vulvovaginal Candidiasis Market Share by Type
Figure 18. Sales Market Share of Drugs for Vulvovaginal Candidiasis by Type (2019-2024)
Figure 19. Sales Market Share of Drugs for Vulvovaginal Candidiasis by Type in 2023
Figure 20. Market Size Share of Drugs for Vulvovaginal Candidiasis by Type (2019-2024)
Figure 21. Market Size Market Share of Drugs for Vulvovaginal Candidiasis by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Drugs for Vulvovaginal Candidiasis Market Share by Application
Figure 24. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2019-2024)
Figure 25. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2023
Figure 26. Global Drugs for Vulvovaginal Candidiasis Market Share by Application (2019-2024)
Figure 27. Global Drugs for Vulvovaginal Candidiasis Market Share by Application in 2023
Figure 28. Global Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Application (2019-2024)
Figure 29. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2019-2024)
Figure 30. North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country in 2023
Figure 32. U.S. Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Drugs for Vulvovaginal Candidiasis Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Drugs for Vulvovaginal Candidiasis Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country in 2023
Figure 37. Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region in 2023
Figure 44. China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (Kilotons)
Figure 50. South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country in 2023
Figure 51. Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2025-2030)
Figure 65. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2025-2030)
Figure 66. Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2025-2030)
